Julie Lemieux
Overview
Explore the profile of Julie Lemieux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen Van Long F, Poirier B, Desbiens C, Perron M, Paquet C, Ouellet C, et al.
Cancer Treat Rev
. 2025 Mar;
135:102909.
PMID: 40054315
Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors represent the most common types of early-stage breast cancer. However, their response to adjuvant systemic treatments varies widely...
2.
Turcotte V, Guillaumie L, Lemay M, Dionne A, Lemieux J, Labbe A, et al.
Curr Oncol
. 2025 Jan;
32(1).
PMID: 39851961
Background: Adjuvant endocrine therapy (AET) is prescribed for 5-10 years to women with hormone-sensitive breast cancer to prevent recurrence. However, a significant proportion of women do not adhere to AET....
3.
Assan O, Memoli V, Guillaumie L, Turcotte V, Lemay M, Dionne A, et al.
J Cancer Surviv
. 2024 May;
PMID: 38702555
Purpose: Adjuvant endocrine therapy (AET) reduces recurrence risk after hormone receptor-positive breast cancer, but non-adherence is common. We pilot-tested SOIE, a program to enhance AET experience and adherence, to assess...
4.
Brearty C, Bisaillon L, Dorval M, Nabi H, Desbiens C, Lemieux J, et al.
Curr Oncol
. 2024 Feb;
31(2):801-817.
PMID: 38392053
Objective: This study investigated if fear of cancer recurrence (FCR) levels and the proportion of women having a clinical level of FCR differed by whether women had or had not...
5.
Ribeiro Paula R, Cusson M, Bertrand N, Bouchard S, Chantigny M, Lemieux J, et al.
Waste Manag
. 2024 Feb;
177:177-181.
PMID: 38330513
Assessments of greenhouse gas (GHG) emissions in managed areas are facing various challenges. A non-flow-through, non-steady-state (NFT-NSS) chamber coupled to a frame permanently inserted into the landfilled substrates is a...
6.
Theriault K, Ben Moussa M, Perron M, Desbiens C, Poirier B, Poirier E, et al.
Breast J
. 2024 Jan;
2024:5920505.
PMID: 38223556
Aim: To examine the clinical management of metaplastic breast cancer (MeBC), particularly the role of chemotherapy. Methods: This retrospective study included patients with MeBC ( = 73) from a tertiary...
7.
Goodwin P, Chen B, Gelmon K, Whelan T, Ennis M, Lemieux J, et al.
J Clin Oncol
. 2023 Sep;
41(35):5356-5362.
PMID: 37695982
JCO Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin ( placebo) did not affect invasive disease-free...
8.
Schmid P, Cortes J, Joaquim A, Martinez Janez N, Morales S, Diaz-Redondo T, et al.
Breast Cancer Res
. 2023 Jun;
25(1):67.
PMID: 37308971
Background: Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of...
9.
Hershman D, Chen B, Sathe C, Parulekar W, Lemieux J, Ligibel J, et al.
Breast Cancer Res Treat
. 2023 May;
200(1):93-102.
PMID: 37157006
Background: The MA32 study investigated whether 5 years of metformin (versus placebo) improves invasive disease-free survival in early-stage breast cancer (BC). Non-adherence to endocrine therapy (ET) and medications for chronic...
10.
Audet S, Doyle C, Lemieux C, Tardif M, Gauvreau A, Simonyan D, et al.
Curr Oncol
. 2023 Feb;
30(2):2061-2072.
PMID: 36826121
Our primary objective was to determine the proportion of trials that report the number of patients assessed for eligibility before randomization. We performed the systematic retrieval and analysis of all...